Lupin Launches Paliperidone Extended-Release Tablets in the

Mumbai, Baltimore, October 20, 2022: Global pharma major Lupin Limited (Lupin) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, to market a generic equivalent of Invega® Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg, of Janssen Research and Development, LLC.

Related Keywords

South Africa , Mumbai , Maharashtra , India , Asia Pacific , Shweta Munjal , Janssen Research , Johnson Corporation New Jersey , Lupin Limited , Corporate Communications , Biotechnology Pharmaceuticals , Paliperidone Extended Release Tablets , Extended Release Tablets , Latin America , Middle East , Great Place , Global Head , Johnson Corporation New , Biotechnology , Pharmaceuticals , Branches Of Biology , Chemical Compounds , Cnx Nifty , Indian Companies Established , Johnson Amp , Magnesium In Biology , Organic Compounds , Paliperidone , Piperidines , Prolactin Releasers , Pseudoephedrine ,